Palatin Technologies (PTN)
Develops melanocortin agonists for rare obesity disorders through a partner-led pipeline.
Something off on this page? Send us feedback.
Develops receptor-selective melanocortin agonists, focusing internally on rare MC4R-pathway obesity disorders. It funds development through licenses and collaborations, while partners control several assets and external providers support research and manufacturing.
Develops receptor-selective melanocortin agonists, centered on next-generation MC4R programs for hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. Its prioritized injectable peptide and oral small-molecule candidates remain in preclinical, IND-enabling work, while bremelanotide is an obesity and GLP-1 adjunct proof-of-concept program.
Generates current revenue from licenses, collaboration research reimbursements, contingent milestones and royalties rather than its own medicine sales. Partners control the retinal-disease assets, dry-eye candidate PL9643 and worldwide Vyleesi rights; the company performs collaborative research and depends on contractors, CROs and external manufacturers for substantial development work. Its only reportable segment is life science.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Target |
|---|---|---|---|
| May 14, 2026 | Industrial Alliance Securities | Target | $47.50 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $10.2M · Total debt $286.7K · Total assets $13.2M · Shareholders' equity $10.6M
- Revenue
- $3.9M
- Operating income
- −$1.6M
- Net income
- −$1.4M
No dividends on record.
| Institutions25 holders · as of Mar 31, 2026 | 43.34% | 771.1K shares | |
| Otherremainder | 56.66% | 1.01M shares |
1.78M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Driehaus Capital Management LLCInstitution | 9.37% | 166,713 | 13Fas of Mar 31, 2026 |
Janus Henderson Group PLCInstitution | 7.87% | 140,000 | 13Fas of Mar 31, 2026 |
Logos Global Management LPInstitution | 7.87% | 140,000 | 13Fas of Mar 31, 2026 |
AuGC BioFund LPInstitution | 5.29% | 94,212 | 13Gfiled Apr 23, 2026 ↗ |
Ra Capital Management, L.P.Institution | 3.93% | 70,000 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Rhythm Pharmaceuticals
Direct MC4R rival in rare neuroendocrine obesity.
- Novo Nordisk (ADR)
Scale leader in chronic weight management with Wegovy.
- Eli Lilly
Leading GLP-1/GIP obesity franchise with Zepbound.
- AbbVie
Dual rival in dry eye and ulcerative colitis.
- Bausch + Lomb
Prescription dry-eye leader through XIIDRA and MIEBO.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Palatin Technologies | $13.08 | +13.64% | $22.8M | — | — | 1.8 | — |
| Rhythm Pharmaceuticals | $105.44 | +0.66% | $7.23B | — | — | 30.1 | +46.9% |
| Novo Nordisk (ADR) | $47.45 | +1.49% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Eli Lilly | $1,160.08 | +0.06% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| AbbVie | $261.54 | −0.06% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Bausch + Lomb | $18.00 | −0.06% | $6.43B | — | 18.1 | 1.2 | +9.1% |
| Median | 38.9 | 18.5 | 7.2 | +10.2% |